Presented by Psychedelics.media

Psychedelic Roundtable Symposium


The future of psychedelic medicine is taking shape.

Where Business Meets Science

An international gathering of clinicians, researchers, pharmaceutical leaders and investors examining the science, clinical pathways and commercial future of psychedelic medicine.


19–20 March 2027

Melbourne, Australia

7

Expert panels

2

Executive Roundtables



Featured pharmaceutical keynote


3 Industry networking events plus VIP dinner

About PRS27


Where clinical innovation
meets commercial opportunity


Psychedelic medicine is entering a critical phase of development. PRS27 brings together the people advancing its clinical evidence, pharmaceutical innovation, healthcare delivery and commercial infrastructure.

Australia has emerged as an important international market after regulatory changes permitting authorised psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression under specific conditions.


Saturday 20 March 2027

11:55 AM–12:30 PM

Title Sponsor Keynote


Jason Carroll

CEO, Entropy Neurodynamics

Keynote title to be announced.

Former Managing Director, iNova Pharmaceuticals Philippines; General Manager, Janssen Pharmaceutica Philippines; Managing Director, Johnson & Johnson Vietnam. BSc (Flinders), MBA (Deakin).


Title Sponsor: Entropy Neurodynamics

Entropy Neurodynamics

Australian biotechnology company developing psychedelic medicines, including TRP-8803, an intravenous psilocin programme.

Seven panels, two Executive Roundtables

What Can Psychedelic Medicine Learn from the Medicinal Cannabis Industry?

Patient acquisition, clinical adoption and building a sustainable market.

Clinical Models and Patient Access

From clinical evidence to real-world treatment.

Research and Next-Generation Therapies

Science, clinical trials and the pharmaceutical pipeline.

Regulation, Policy and Reimbursement

The framework for wider patient access.

Investment, Capital and Commercialisation

Financing the future of psychedelic medicine.

Technology, AI and Digital Health

Transforming psychedelic medicine through innovation.

Education, Careers and Workforce Development

Preparing the next generation of professionals.


Friday roundtable

From Emerging Medicine to Established Healthcare Industry

Saturday roundtable

The Future of Psychedelic Medicine, Building a Sustainable Global Ecosystem

The panel discussions

Seven conversations shaping the future of psychedelic medicine.

1

PANEL DISCUSSION 1

What Can Psychedelic Medicine Learn from the Medicinal Cannabis Industry?

Lessons from a decade of clinical adoption, regulation, patient access and commercial development in Australia.

2

PANEL DISCUSSION 2

Clinical Models & Patient Access

Building sustainable, scaled and patient-centred models for psychedelic-assisted therapy in Australia and beyond.

3

PANEL DISCUSSION 3

Research & Next-Generation Therapies

Emerging compounds, new formulations and the next wave of clinical innovation.

4

PANEL DISCUSSION 4

Regulation, Policy & Reimbursement

The frameworks needed to support safe, scaled and sustainable access to psychedelic medicine.

5

PANEL DISCUSSION 5

Investment, Capital & Commercialisation

Building a viable and scalable psychedelic medicine industry in the Asia-Pacific region.

6

PANEL DISCUSSION 6

Technology, AI & Digital Health

How new technologies, data and AI are improving safety, access and outcomes in psychedelic medicine.

7

PANEL DISCUSSION 7

Education, Careers & Workforce Development

Building the people, training and professional pathways for a sustainable psychedelic medicine sector.

Featured speakers

programme speakers


Gary Mackenzie

Executive Producer / Editor, Psychedelics.media

Dr Alana (Lani) Roy

Chair, Australian Multidisciplinary Association for Psychedelic Practitioners (AMAPP)

A registered psychologist, social worker and psychedelic-assisted therapy practitioner. As Chair of AMAPP, she advocates for evidence-informed psychedelic practice and professional standards.

Dr Julian Dodemaide

Consultant Psychiatrist, Forest Medicine

Consultant psychiatrist and TGA Authorised Prescriber in psychedelic-assisted therapies, with a particular interest in emerging approaches to psychedelic-assisted therapy.

Dr Mitchell McKean

Director of Medicine, Ipswich Hospital; Chief Medical Officer, MINDR

Director of Medicine at Ipswich Hospital and Senior Lecturer at The University of Queensland, with expertise in clinical pharmacology and toxicology. As Chief Medical Officer of MINDR, he provides medical leadership for its approach to innovative mental health treatments.

Dr Chris Corney

Physician and Senior Lecturer, The University of Queensland; CEO, MINDR

A specialist in General Medicine, focused on advancing new approaches to mental healthcare. As CEO of MINDR, he works on translating emerging evidence into practical clinical applications.

Professor Paul Fitzgerald

Head of the School of Medicine and Psychology, Australian National University

An academic psychiatrist who has conducted an extensive series of clinical trials developing new treatments for mental health conditions. He established the first national psychedelic therapies outcomes registry.

Dr Bernadette Fitzgibbon

Director of Psychiatry Research, Paratus Clinical; Associate Professor, Australian National University

A neuroscientist whose work includes the development and clinical investigation of psychedelic therapies, including large multi-site clinical trials.

Dr Anne Yee

Associate Professor; Consultant Addiction Psychiatrist, Monash University Malaysia

Works in addiction psychiatry, substance use and dual diagnosis. Honorary Secretary of the Addiction Medicine Association of Malaysia, with more than 110 peer-reviewed papers.

Sabba Nazhand

Co-Founder and CEO, Safar

Co-Founder and CEO of Safar, an agentic care platform for therapists and wellness practitioners. A technology executive with more than 20 years in sales and leadership.

Tony “Jack the Bear” Mantz

Men's Mental Health Advocate. A music industry veteran and mastering engineer who speaks openly about addiction, trauma and recovery.

Karin Hauser

Natural MedTech. Works at the intersection of pharmaceutical innovation, commercialisation and patient access.

Melissa Warner

Programs and Innovation Lead, Karuna Mental Health; Director, Anam Cara Centre

A multidisciplinary researcher, educator and contemplative therapist working at the intersection of psychedelic-assisted therapy, immersive technology and mental healthcare.

Merryn Spence

Director of Network and Outreach, Students for Sensible Drug Policy; Community Engagement Manager, Fireside Project

An educator, consultant and harm reduction advocate with more than 15 years of experience in the psychedelic field. Her work spans practitioner training and community engagement.

Pukar Makani Nepal

Executive Director, Ancient Modern Institute; Neuroscience Student and Researcher, Johns Hopkins University


Additional international speakers, industry executives and investment representatives to be announced. Final participation, titles and sessions subject to confirmation.

Secure your place at PRS27


Student Delegate

AU$495

For eligible students and emerging professionals.

  • Access to the main PRS27 Symposium on 20 March

General Delegate

AU$895

19 & 20 March

  • Access to the main PRS27 Symposium on 19 & 20 March, including the full programme and networking opportunities
Recommended

VIP Delegate

AU$1,495

Principal benefit: VIP Dinner admission

  • Full access to the main symposium, plus exclusive VIP access, the Official Welcome Networking Reception on 19 March and the PRS27 VIP Dinner on 20 March, subject to availability.

Opening Networking Ticket · 19 March · AU$95.

Access to the Official Welcome Networking Reception (5:00–7:00 PM) only.


Venue and networking

Le Méridien Melbourne


20 Bourke Street, Melbourne, Victoria

19–20 March 2027

In the CBD near Parliament House and the theatre precinct. Melbourne is recognised for its medical research institutions, universities, healthcare expertise and biotechnology sector.

Networking

Friday Welcome Networking Reception

19 March, 5:00–7:00 PM

Saturday Symposium Networking Reception

20 March, 4:30–6:00 PM

Exclusive PRS27 VIP Dinner

20 March, 7:00–9:00 PM

For VIP delegates, selected speakers, investors, senior clinicians, researchers, healthcare executives and invited industry guests. Subject to availability.

Programme

Friday 19 March 2027


Time

Session

1:00–3:00 PM

Registration and delegate arrivals

3:00–3:45 PM

Opening Industry Panel

What Can Psychedelic Medicine Learn from the Medicinal Cannabis Industry?

Patient acquisition, clinical adoption and building a sustainable market.

3:45–4:00 PM

Break

4:00–5:00 PM

Executive Roundtable

From Emerging Medicine to Established Healthcare Industry

5:00–7:00 PM

Official Welcome Networking Reception

Programme · Morning


Saturday 20 March

Time

Session

8:45–9:30 AM

Registration, tea, coffee and networking

9:30–9:40 AM

Official Welcome

9:40–10:20 AM

Panel 1 · Clinical Models and Patient Access

Proposed: Dr Julian Dodemaide, Dr Mitchell McKean, Dr Chris Corney

10:20–11:00 AM

Panel 2 · Research and Next-Generation Therapies

Proposed: Professor Paul Fitzgerald, Dr Bernadette Fitzgibbon, Dr Anne Yee

11:00–11:15 AM

Morning tea

11:15–11:55 AM

Panel 3 · Regulation, Policy and Reimbursement

Proposed: Dr Alana (Lani) Roy, Chair, AMAPP

Additional panellists to be announced.

Programme · Afternoon

Saturday
20 March


Programme and proposed speaker allocations are subject to confirmation.

Time

Session

11:55 AM–12:30 PM

Title Sponsor Keynote

Jason Carroll, CEO, Entropy Neurodynamics

12:30–1:15 PM

Networking lunch

1:15–1:55 PM

Panel 4 · Investment, Capital and Commercialisation

Panellists to be announced

1:55–2:35 PM

Panel 5 · Technology, AI and Digital Health

Proposed: Sabba Nazhand, Melissa Warner

2:35–2:50 PM

Afternoon tea

2:50–3:30 PM

Panel 6 · Education, Careers and Workforce Development

Proposed: Merryn Spence

Additional panellists to be announced.

3:30–4:30 PM

Closing Executive Roundtable

The Future of Psychedelic Medicine, Building a Sustainable Global Ecosystem

Proposed participant: Pukar Makani Nepal

4:30–6:00 PM

Symposium Networking Reception

7:00–9:00 PM

Exclusive PRS27 VIP Dinner

Who should attend

Psychiatrists and psychologists

Clinical models, patient access and real-world treatment.

Pharmaceutical and biotechnology companies

Clinical trials, next-generation therapies and the pharmaceutical pipeline.

Investors and financial professionals

Business models, partnerships and financial structures through the Investment panel and Roundtables.

Researchers and academic institutions

Clinical evidence, neuroscience and emerging research.

Healthcare entrepreneurs and industry executives

Healthcare delivery, commercialisation and industry partnerships.

Students, educators and emerging professionals

Qualifications, competencies, standards and training pathways through the Education, Careers and Workforce Development panel.

Title Sponsor

Entropy Neurodynamics


Confirmed Title Sponsor of PRS27, supporting the Title Sponsor Keynote on Saturday 20 March.

Confirmed Title Sponsor · entropyneurodynamics.com

Sponsorship and industry partnerships


Connect with healthcare professionals, pharmaceutical executives, researchers, investors, educators and decision-makers.

Partnership opportunities

Panel sponsorship, exhibition and networking partnerships.

Publication and digital exposure

Conference publication advertising and digital exposure. A PRS27 conference booklet and online industry directory are being developed.

Why partner

Direct access to a senior professional audience

Brand positioning within an emerging healthcare sector

Thought leadership opportunities

Brand visibility across the symposium

Clinical and industry networking

Relationship development

Access to emerging commercial and healthcare opportunities

Programme participation remains editorially independent and is not included automatically with sponsorship.

Supporting partners

MINDR

Investor Deck

AMAPP, Australian Multidisciplinary Association for Psychedelic Practitioners

Safar

Enquire about partnership

Pharmaceutical companies, biotechnology businesses, medical technology firms and industry partners are invited to enquire about meaningful professional engagement, industry visibility and access to a relevant audience.

Business of Psychedelics: PRS27 Special Edition


March 2027. News, insights and opportunities from the Asia-Pacific summit for psychedelic medicine, investment and clinical innovation.

Presented by Psychedelics.media

Inside this edition

  • The PRS27 Programme
  • Key Speakers & Roundtables
  • Investment & Commercialisation
  • Regulation, Policy & Reimbursement
  • Technology, AI & Digital Health
  • A Sustainable Ecosystem for Psychedelic Medicine

Presented by


Where Business Meets Science

A specialist publication covering the business, science, regulation and commercial development of psychedelic medicine through news, analysis, executive interviews and its Business of Psychedelics publication.

PRS27 extends that mission by bringing the industry together in person.

Frequently asked questions

When is PRS27?

Friday 19 and Saturday 20 March 2027.


Where is it held?

Le Méridien Melbourne, 20 Bourke Street, Melbourne, Australia.


Who should attend?

Psychiatrists, psychologists, researchers, pharmaceutical executives, investors, healthcare entrepreneurs, educators and students.


Is the focus scientific or business?

Both.


Is networking included?

General events are included with delegate admission. The VIP Dinner is included with the VIP Delegate ticket.


Can I meet speakers and executives?

Yes, through dedicated networking sessions.


Can I sponsor or exhibit?

Yes, subject to package availability.


Will the programme change?

It is subject to final speaker, moderator and session confirmations.


How much are tickets?

General AU$895, Student AU$495 and VIP AU$1,495. A Networking Ticket for the 19 March Official Welcome Networking Reception is available for AU$95.

Where Business Meets Science


Be part of the conversation

19–20 March 2027 | Melbourne, Australia

The next chapter of psychedelic medicine will be shaped by people who understand both its scientific potential and the realities of building a sustainable healthcare industry. Join them at PRS27.

www.prs27.com